Breaking News

Aurisco Expands Oligonucleotide Capacity

OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

Aurisco Pharmaceutical, a pharmaceutical contract research, development and manufacturing organization (CRDMO) expanded its oligonucleotide manufacturing capacity. The new OligoPilot 2000TM solid-phase synthesizer, from Cytiva, completes Aurisco Biotech’s pilot scale cGMP plant and provides immediate capacity availability to accelerate customer’s clinical programs as well as Aurisco’s generic oligonucleotide pipeline. Peng Zhien, chairman of Aurisco, said: “The comp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters